Annexon Inc
Annexon Inc (ANNX) Historical Volatility
ANNX's 30 day historical volatility is 76.17%, in the 61st percentile of readings over the past year. This is an average percentile, meaning Annexon Inc shares have moved roughly in line with their typical range. ANNX's 30 day implied volatility sits at 366.40%, with an IV Rank of 96.43%, leaving IV 290.23 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking ANNX historical volatility helps you see how much Annexon Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ANNX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ANNX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ANNX's 30 day historical volatility, or ANNX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ANNX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →